195877-55-5

Basic information

• Product Name: 4-(2-benzyloxycarbonylamino-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(2-benzyloxycarbonylamino-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 195877-55-5
• Molecular Weight: 390.48
• Mol File: 195877-55-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(2-benzyloxycarbonylamino-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-benzyloxycarbonylamino-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester(195877-55-5)
• EPA Substance Registry System: 4-(2-benzyloxycarbonylamino-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester(195877-55-5)

Safety Data

• Hazardous Substances Data: 195877-55-5(Hazardous Substances Data)

Upstream product

• 195877-49-7 4-[(S)-2-Azido-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-48-6 4-[3-(4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-52-2 4-(2-azido-2-methoxycarbonyl-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-50-0 S-2-azido-3-(N-Boc-piperidyl)-propionic acid 
• 195877-53-3 4-(2-amino-2-methoxycarbonyl-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1822-32-8 3-(4-piperidyl)propionic acid 
• 195877-54-4 tert-butyl 4-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methoxy-3-oxopropyl]piperidine-1-carboxylate 
• 154775-43-6 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 

Downstream Products

• 195877-57-7 4-(2-benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-56-6 4-(3-acetoxy-2-benzyloxycarbonylamino-3-cyano-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1001647-40-0 C₂₈H₃₅N₃O₆ 

Relevant articles and documents

Compounds and Compositions as Channel Activating Protease Inhibitors

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.